biogen should of bought elan before tysabri became blockbuster.now they will never recover 3.25bln plus hundreads of mlns every year in royalties.b-12 appears to be a flop,avonex intake grows 2% for the last several years and is highly ineffective.lousy,lousy mgmt.
Biogen owns Tysabri instead of sharing with with Elan. After selling the rights of Tysabri to BIIB Elan became nothing more than a holding company with a bunch of cash and no products in the pipeline. There was no reason for BIIB to buy it.
You would have to be on crack to think that BG12/Tecfidera has been anything but a flop. Did you read their earnings report at all?
Plus they have several other treatments scheduled to be released in 2014.
Your opinions are as bad as your spelling.
just for your info:biogen will pay royalties from sales and itself post profit after all the expences.try to analyze the figures for the last couple qtrs,if you can,and u will see,perhaps,what i was talking about